WAYNE, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the establishment of the Teleflex Center for Antimicrobial Protection (TCAP) as a strategic branch of its Vascular Access business unit led by Chuck Gartner, Director of Marketing - Strategic Initiatives. "Teleflex strives to deliver vascular access products that are designed to benefit both clinicians and patients by helping to reduce vascular access related com ...

WAYNE, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, August 1, 2024. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, teleflex.com. An audio replay of the call will be available beginn ...

WAYNE, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, August 1, 2024. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, teleflex.com. An audio replay of the call will be available beginn ...

Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements. Most Powerful Force Impacting Stock Prices Harnessing the Power of Earnings Estimate Revisions Earnings Estimate Revisions for Teleflex Analysts ...

Investors with an interest in Medical - Instruments stocks have likely encountered both Teleflex (TFX) and SONOVA HOLDING (SONVY) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank emphasizes companies with positive estimat ...

Hims & Hers Health's earnings are expected to surge 272.7% in 2024 compared with the industry's 16.6%. HIMS' earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 79.2%. Its shares have surged 136.4% against the industry's 28% decline in the past year. HIMS sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks here. Medpace, carrying a Zacks Rank #2 (Buy) at present, has an estimated 20 ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? Developed ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 1-5353 TELEFLEX INCORPORATED (Exact name of registrant as specified in its charter) Delaware 23-1147939 (State or other jurisdicti ...

Financial Data and Key Metrics Changes - For Q1 2024, the company reported revenues of $737.8 million, a 3.8% increase year-over-year on both GAAP and constant currency basis [83] - Adjusted earnings per share (EPS) for the first quarter was $3.21, reflecting a 3.9% increase compared to the prior year [7][83] - Net interest expense increased to $21 million from $17.5 million in the prior year, primarily due to higher interest rates and increased debt from the Palette acquisition [7] - Adjusted gross margin was 61.1%, a 170 basis point increase year-over-year, driven by the termination of the MSA and the acquisition of Palette [64] - The adjusted tax rate for Q1 2024 was 13.2%, up from 11.8% in the prior year, mainly due to European tax reforms [7] Business Line Data and Key Metrics Changes - Interventional Urology revenue was $79.7 million, a 6.1% increase year-over-year, driven by Barrigel revenue from the Palette acquisition [5] - Interventional revenue increased by 15.4% year-over-year to $134.7 million, led by balloon pumps and complex catheters [61] - Surgical business revenue was $105.5 million, a 7.1% increase year-over-year, with strong performance in chest drainage instrumentation [61] - OEM revenue grew 13.6% year-over-year to $87.7 million, with strong demand for microcatheters [85] Market Data and Key Metrics Changes - Americas revenues decreased by 1.5% year-over-year to $406.3 million, impacted by the loss of MSA revenues [4] - EMEA revenues increased by 9.7% year-over-year to $159.6 million, with double-digit growth in interventional and interventional urology [4] - Asia revenues were $84.2 million, an 11.2% increase year-over-year, with strong growth in China, India, and Southeast Asia [84] Company Strategy and Development Direction - The company aims to drive durable growth through organic opportunities and innovation, while also focusing on disciplined capital allocation [68] - The integration of Palette Life Sciences is progressing well, expected to contribute significantly to growth in the coming years [68] - The company is focused on tuck-in acquisitions and scale transactions, with a strong emphasis on maintaining a disciplined approach to M&A [25][110] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the 2024 revenue growth guidance of 3.75% to 4.75%, despite the loss of MSA revenues [8] - The company anticipates a positive trend in gross margins and operating margins, with expectations for continued improvement in the second half of 2024 [48][66] - Management noted that the operating environment remains strong, with utilization of products returning to pre-pandemic levels [83] Other Important Information - The company expects a foreign exchange headwind of approximately $12 million for 2024, impacting revenue growth [89] - Cash flow from operations for Q1 was $112.8 million, an increase from $84.3 million in the prior year, attributed to favorable operating results [88] - The company is actively training sales representatives for the Palette product line, with full integration expected by the end of 2024 [62] Q&A Session Summary Question: What are the drivers of growth for Palette? - Management indicated that growth for Palette is primarily driven by market expansion and adoption within the existing customer base, with additional sales representatives expected to enhance market presence [39] Question: Why was the full-year guidance not raised despite a strong Q1? - Management explained that while Q1 performance was strong, the guidance was conservative due to the need to monitor ongoing trends and the impact of foreign exchange [20][38] Question: What is the outlook for UroLift? - Management confirmed expectations for UroLift to achieve 7.5% growth in 2024, despite challenges in the office side of service and sales force training [115] Question: How does the company view the competitive landscape in the OEM business? - Management noted that while there is competitive noise, the underlying demand remains strong, and they anticipate double-digit growth for OEM throughout the year [69] Question: What are the expectations for gross margin expansion in 2025? - Management expressed optimism about gross margin expansion due to continuous improvement programs and the ramp-up of Palette, which is expected to become accretive to operating margins [145]

Teleflex Incorporated 5/2/2024 Conference Call | --- | --- | --- | --- | --- | |--------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------|-------|-------| | | | | | | | The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on Investors) | | | | | | An audio replay of the call will be available beginning at 11:00 am Eastern Time on May 2, 2024 either on ...